Biljana Jekic
Research Subjects
Research Interests
Biljana Jekic has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Branka Popovic
Department of Human Genetics, School of Dental Medicine, University of Belgrade, Belgrade, Serbia
3 shared publications - Jelena Milasin
Department of Human Genetics, School of Dental Medicine, University of Belgrade, Belgrade, Serbia
3 shared publications - Ivana Novakovic
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
2 shared publications Ljiljana Lukovic
2 shared publicationsVera Bunjevacki
2 shared publicationsGoran Radunovic
1 shared publication
Latest Publications
- 13 April 2012
- Vol. 30 (2) , 178-83
Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis.
Identifying genetic predictors of methotrexate (MTX) treatment response in patients with rheumatoid arthritis (RA) may have great importance for optimising drug doses required for clinical benefit without toxicity. In a group of 125 RA patients treated with MTX we investigated whether selected polymorphisms in genes relevant for MTX action (aminoimidazole-4-carboxiamide ribonucleotide transformylase, ATIC, and dihydrofolate reductase, DHFR) modulate disease activity and/or have impact on therapy side effects. The efficacy of treatment was estimated both by the disease activity score in 28 joints (DAS28), based on EULAR criteria, and relative DAS28 (rDAS28) score. Adverse drug events (ADEs) were also recorded. RA patients were genotyped using the PCR-RFLP method, followed by an association study between ATIC -129T>G, DHFR -216T>C and DHFR -317A>G polymorphisms and the efficacy and toxicity of MTX. According to the EULAR response criteria, 96 RA patients (76.8%) were classified as responders (good/moderate response) and 29 (23.2%) as non-responders (poor response). rDAS28 values ranged from -0.01 to 0.80 (mean value 0.31±0.19). Among 125 patients enrolled in this study 39 experienced at least one side effect. The DHFR -317AA genotype was associated with the less favourable response (reduction in rDAS28 score, p=0.05). None of the analysed polymorphisms was associated with MTX toxicity. RA patients with DHFR-317AA genotype had less favourable response to MTX. Further studies in larger patient populations are necessary to confirm the relationship between the analysed polymorphisms and MTX treatment response.
- 13 April 2012
- Vol. 30 (2) , 178-83
Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis.
Identifying genetic predictors of methotrexate (MTX) treatment response in patients with rheumatoid arthritis (RA) may have great importance for optimising drug doses required for clinical benefit without toxicity. In a group of 125 RA patients treated with MTX we investigated whether selected polymorphisms in genes relevant for MTX action (aminoimidazole-4-carboxiamide ribonucleotide transformylase, ATIC, and dihydrofolate reductase, DHFR) modulate disease activity and/or have impact on therapy side effects. The efficacy of treatment was estimated both by the disease activity score in 28 joints (DAS28), based on EULAR criteria, and relative DAS28 (rDAS28) score. Adverse drug events (ADEs) were also recorded. RA patients were genotyped using the PCR-RFLP method, followed by an association study between ATIC -129T>G, DHFR -216T>C and DHFR -317A>G polymorphisms and the efficacy and toxicity of MTX. According to the EULAR response criteria, 96 RA patients (76.8%) were classified as responders (good/moderate response) and 29 (23.2%) as non-responders (poor response). rDAS28 values ranged from -0.01 to 0.80 (mean value 0.31±0.19). Among 125 patients enrolled in this study 39 experienced at least one side effect. The DHFR -317AA genotype was associated with the less favourable response (reduction in rDAS28 score, p=0.05). None of the analysed polymorphisms was associated with MTX toxicity. RA patients with DHFR-317AA genotype had less favourable response to MTX. Further studies in larger patient populations are necessary to confirm the relationship between the analysed polymorphisms and MTX treatment response.
- Open Access
- 1 January 2007
- Published by National Library of Serbia in Stomatoloski glasnik Srbije
- Vol. 54 (3) , 153-159
Analysis of the anti-apoptotic protein bcl-2 in oral squamous cell carcinoma
Aim: The aim of this study was to analyze the presence of the anti-apoptotic protein bcl-2 in oral squamous cell carcinoma and determine its potential role in the development and progression of this type of tumor. Materials and methods: The expression of bcl-2 was determined in 28 paraffin blocks of oral squamous cell carcinoma using the immunohistochemical method. The percentage of the immuno-reactive cells in positively stained tumor regions was determined using the microscopic analysis and Ozaria software. Results: Positive immunohistochemical test was observed in 19 out of 28 samples (68%) as follows: in 11 samples there was a low (+), in four a moderate (++) and in the last four a high percentage (+++) of stained cells. In the group of patients at the low stage of the disease (T2), 50% of tumor samples showed bcl-2 protein expression whereas in the higher stages (T3 and T4) of positively stained samples, this percentage was 67%. There was a trend of an increasing number of cells with positive bcl-2 staining in the tumors of higher clinical stages but not the level of bcl-2 protein expression. Conclusion: Both parameters, the presence of bcl-2 staining and the percentage of cells with bcl-2 immunoexpression, may act as additional prognostic parameters that indicate an increased proliferative tumor potential.
- 1 January 2007
- Published by National Library of Serbia in Stomatoloski glasnik Srbije
- Vol. 54 (3) , 153-159
Open AccessAnalysis of the anti-apoptotic protein bcl-2 in oral squamous cell carcinoma
Aim: The aim of this study was to analyze the presence of the anti-apoptotic protein bcl-2 in oral squamous cell carcinoma and determine its potential role in the development and progression of this type of tumor. Materials and methods: The expression of bcl-2 was determined in 28 paraffin blocks of oral squamous cell carcinoma using the immunohistochemical method. The percentage of the immuno-reactive cells in positively stained tumor regions was determined using the microscopic analysis and Ozaria software. Results: Positive immunohistochemical test was observed in 19 out of 28 samples (68%) as follows: in 11 samples there was a low (+), in four a moderate (++) and in the last four a high percentage (+++) of stained cells. In the group of patients at the low stage of the disease (T2), 50% of tumor samples showed bcl-2 protein expression whereas in the higher stages (T3 and T4) of positively stained samples, this percentage was 67%. There was a trend of an increasing number of cells with positive bcl-2 staining in the tumors of higher clinical stages but not the level of bcl-2 protein expression. Conclusion: Both parameters, the presence of bcl-2 staining and the percentage of cells with bcl-2 immunoexpression, may act as additional prognostic parameters that indicate an increased proliferative tumor potential.
- 1 April 2006
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 166 (2) , 163-165
Lack of TP53 and FMS gene mutations in children with myelodysplastic syndrome
- 1 April 2006
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 166 (2) , 163-165
Lack of TP53 and FMS gene mutations in children with myelodysplastic syndrome